Prophylaxis of HAE Attacks: A Randomized Trial of Oral Plasma Kallikrein Inhibition with Avoralstat

Publication date: Available online 11 May 2016
Source:Journal of Allergy and Clinical Immunology
Author(s): Emel Aygören-Pürsün, Markus Magerl, Jochen Graff, Inmaculada Martinez-Saguer, Wolfhart Kreuz, Hilary Longhurst, Iman Nasr, Murat Bas, Ulrich Straßen, Lei Fang, Melanie Cornpropst, Sylvia Dobo, Phil Collis, William P. Sheridan, Marcus Maurer

Teaser

Uncontrolled activity of plasma kallikrein is essential in release of bradykinin, the mediator of increased vascular permeability and swelling attacks in hereditary angioedema. In this 28-day randomized, placebo-controlled cross-over trial in patients with hereditary angioedema, prophylactic use of avoralstat, an orally administered plasma kallikrein inhibitor, significantly reduced the rate of angioedema attacks.


from #ENT via xlomafota13 on Inoreader http://ift.tt/1sdFCOJ
via IFTTT